Britain’s cardiology diagnostics solution Ultromics raises €48 million to detect elusive forms of heart failure

Oxford-based Ultromics, an innovator in AI-driven cardiology diagnostics solutions, today announced it has raised €48 million through its Series C funding round.

The funding round was co-led by L&G, Allegis Capital, and Lightrock. It also received continued support from Oxford Science Enterprises, GV, Blue Venture Fund, and Oxford University. Additionally, the University of Chicago Medicine and UPMC Enterprises, the innovation, commercialisation and investment arm of UPMC (University of Pittsburgh Medical Center) participated in the round.

“The reality is, hospitals already have the data, they just haven’t had the tools to extract diagnostic signals from it. By analysing routine echocardiograms with AI, we’re helping clinicians identify high-risk patients earlier, enabling intervention before disease progresses,” said Ross Upton, PhD, CEO and Founder, Ultromics. “We’ve spent years building our platform to fit into clinical workflows, with no extra hardware and no new friction, and this funding helps us scale that across the U.S. at a moment when health systems are actively looking to combat the growing heart failure crisis.”

Founded in 2017, Ultromics offers the first FDA-cleared, Medicare-reimbursed AI technology to help clinicians detect Heart Failure with Preserved Ejection Fraction (HFpEF) and cardiac amyloidosis – allegedly two of the most elusive forms of heart failure.

According to the company, conventional solutions often rely on subjective interpretation of echocardiograms, leading to missed or delayed diagnoses. Up to 64% of HFpEF cases go undiagnosed, and cardiac amyloidosis is frequently mistaken for more common forms of heart disease, leaving patients untreated until symptoms worsen or cardiac arrest occurs.

Ultromics addresses this diagnostic blind spot by using AI in its EchoGo platform to extract hidden disease signals from standard echocardiograms, reportedly enabling earlier, more accurate detection of complex heart conditions, without requiring new hardware or disrupting clinical workflows.

The company will use the proceeds of the round to expand across the US and other key markets to bring that capability to the hospitals and echo labs that see the highest volume of at-risk patients, aiming to make AI-enhanced diagnostics a default step in the cardiac examinations.

Ultromics is ​also expanding its product pipeline to include additional cardiac conditions, new distribution channels , and deeper partnerships with health systems and clinical leaders.

Ultromics has already analysed more than 430,000 echocardiograms to date. In clinical studies, EchoGo reportedly improved the detection of HFpEF by 73.6% when compared with standard clinical risk scores. The company’s latest diagnostic model for cardiac amyloidosis, validated in a global study of 18 institutions, outperformed current clinical risk scores while distinguishing disease from similar conditions.

“Ultromics has established itself as an early-mover in the large and underserved cardiovascular disease market, having developed one of the first commercially available AI-powered diagnostic echocardiogram technologies,” said Alastair Stewart, Head of Investments, Venture Capital, at L&G. “This successful Series C round is a testament to the massive opportunity for cutting-edge technology to transform how clinicians can detect and treat serious cardiovascular diseases that impact millions of people every year.”

With growing adoption and partnerships across flagship institutions, including University of Chicago Medicine, University Hospitals Cleveland, Northwestern University, and Mayo Clinic, Ultromics is building regional clusters of clinical and commercial traction, particularly in high-prevalence regions like the USA’s Midwest.

The platform is designed to assist hospitals by reducing unnecessary tests, streamlining workflows, and enabling earlier initiation of treatment. This approach aims to enhance the effectiveness of medical interventions while also reducing costs.

“Heart failure and cardiac amyloidosis impact millions of lives and strain healthcare systems, despite new approaches that have the potential to significantly improve patient outcomes. There is a critical need for scalable solutions that enable earlier, mo re accurate diagnosis and elevate the standard of care,” said Umur Hursever, Partner at Lightrock. “Ultromics’ AI-driven technology is already making a real-world impact, improving diagnostic accuracy, supporting clinical decisions, and expanding access to specialist care. The Lightrock team is delighted to support Ultromics’ mission and growing impact.”

In late 2024, the company received FDA Breakthrough Device clearance for EchoGo Amyloidosis, followed in 2025 by the launch of EchoGo Score, a new feature that adds AI-driven probability scoring to EchoGo Heart Failure, helping clinicians detect HFpEF with greater nuance.

“There’s a long-standing blind spot in cardiology where millions of patients with treatable heart failure are missed because their symptoms are subtle and echo images are hard to interpret,” said Victor Westerlind, Managing Director at Allegis Capital. “What’s exciting about Ultromics is how they’re closing that gap. Their platform brings AI and cardiology together in a way that makes it easier for physicians to identify high-risk patients earlier. When paired with the latest treatment advances, it’s a diagnostic win that will help save lives.”

The post Britain’s cardiology diagnostics solution Ultromics raises €48 million to detect elusive forms of heart failure appeared first on EU-Startups.